Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CPRX's Cash to Debt is ranked higher than
96% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. CPRX: No Debt )
CPRX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CPRX's Interest Coverage is ranked higher than
89% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.51 vs. CPRX: No Debt )
CPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 13.33
M-Score: -3.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -56.82
CPRX's ROE (%) is ranked lower than
55% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CPRX: -56.82 )
CPRX' s 10-Year ROE (%) Range
Min: -568.89   Max: -13.75
Current: -56.82

-568.89
-13.75
ROA (%) -47.91
CPRX's ROA (%) is ranked lower than
55% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. CPRX: -47.91 )
CPRX' s 10-Year ROA (%) Range
Min: -291.89   Max: -13.24
Current: -47.91

-291.89
-13.24
ROC (Joel Greenblatt) (%) -25151.22
CPRX's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. CPRX: -25151.22 )
CPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54300   Max: -1217.19
Current: -25151.22

-54300
-1217.19
Revenue Growth (%) -100.00
CPRX's Revenue Growth (%) is ranked lower than
60% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. CPRX: -100.00 )
CPRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -100
Current: -100

EBITDA Growth (%) 1.50
CPRX's EBITDA Growth (%) is ranked higher than
68% of the 504 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.00 vs. CPRX: 1.50 )
CPRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 42
Current: 1.5

0
42
EPS Growth (%) 7.10
CPRX's EPS Growth (%) is ranked higher than
74% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. CPRX: 7.10 )
CPRX' s 10-Year EPS Growth (%) Range
Min: -33.7   Max: 40.8
Current: 7.1

-33.7
40.8
» CPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CPRX Guru Trades in

CPRX Guru Trades in

Q3 2013

CPRX Guru Trades in Q3 2013

Jim Simons 138,500 sh (New)
» More
Q4 2013

CPRX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CPRX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.10
CPRX's P/B is ranked lower than
53% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. CPRX: 5.10 )
CPRX' s 10-Year P/B Range
Min: 1.5   Max: 11.71
Current: 5.1

1.5
11.71
EV-to-EBIT 17.90
CPRX's EV-to-EBIT is ranked higher than
65% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. CPRX: 17.90 )
CPRX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 17.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.60
CPRX's Price/Net Cash is ranked higher than
80% of the 219 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. CPRX: 5.60 )
CPRX' s 10-Year Price/Net Cash Range
Min: 1.36   Max: 9.21
Current: 5.6

1.36
9.21
Price/Net Current Asset Value 5.60
CPRX's Price/Net Current Asset Value is ranked higher than
71% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. CPRX: 5.60 )
CPRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.36   Max: 9.21
Current: 5.6

1.36
9.21
Price/Tangible Book 5.10
CPRX's Price/Tangible Book is ranked lower than
52% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. CPRX: 5.10 )
CPRX' s 10-Year Price/Tangible Book Range
Min: 1.24   Max: 8.6
Current: 5.1

1.24
8.6
Forward Rate of Return (Yacktman) -26.64
CPRX's Forward Rate of Return (Yacktman) is ranked lower than
53% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. CPRX: -26.64 )
CPRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -26.64

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CN2.Germany
Catalyst Pharmaceutical Partners, Inc. was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical Company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. It has two products in development. It is currently evaluating its drug candidate, CPP-109 (its formulation of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 and CPP-115 have both been granted 'Fast Track' status by the FDA for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 and CPP-115 are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. The Company is in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and other selected central nervous disease indications. The Company competes against pharmaceutical companies that are developing or currently marketing therapies for addictive substances. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide